According to filings with the U.S. Securities and Exchange Commission, RENOVARO is raising up to $106,849,547.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Mark Dybul played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About RENOVARO
Renovaro Biosciences, Inc. is a biotechnology company committed to developing advanced allogenic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as HIV and Hepatitis B virus (HBV) infection. F . Our integrated platforms encompass innovative interventions in advanced cell and gene therapies that provide hope for cures and/or life-long remissions for devastating diseases. Because of the relative ease of administration, our potentially ground-breaking interventions could be used throughout the world to transform the lives of millions of people.

To learn more about RENOVARO, visit http://www.renovarobio.com/

Contact:
Mark Dybul, Chief Executive Officer
305-918-1980
https://www.linkedin.com/in/honorable-mark-dybul/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.